人工多能性幹細胞市場- 世界の産業規模、シェア、動向、機会、予測、由来細胞タイプ別、用途別、エンドユーザー別、地域別、競合別、2020-2030F

世界の人工多能性幹細胞（iPSC）市場は、2024年に14億5,000万米ドルと評価され、予測期間を通じて力強い成長を示し、2030年までCAGR9.60％で拡大すると予測されています。

iPS細胞市場は、再生医療や細胞治療におけるダイナミックで将来性の高い分野として浮上しています。iPS細胞は、多能性状態に初期化された成体細胞であり、事実上あらゆる種類の細胞に分化することができます。このユニークな能力により、iPSCは治療開発と生物医学研究の双方において重要な資産となっています。

市場促進要因

慢性疾患の増加

この戦略的方向転換は、従来の治療に代わる持続可能で個別化された治療法として、iPSCベースの治療法に対する信頼の高まりを示すものです。

主な市場課題

安全性と有効性に関する懸念

主要市場動向

個別化医療と患者特異的治療の成長

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の人工多能性幹細胞市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 由来細胞の種類別（肝細胞、線維芽細胞、角化細胞、ニューロン、その他）
  • 用途別（医薬品開発、再生医療、毒性試験、組織工学、細胞療法、疾患モデル）
  • エンドユーザー別（調査機関、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の人工多能性幹細胞市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の人工多能性幹細胞市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の人工多能性幹細胞市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の人工多能性幹細胞市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの人工多能性幹細胞市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Axol Bioscience Ltd.
• Cynata Therapeutics Limited
• Evotec SE
• Fate Therapeutics, Inc.
• FUJIFILM Cellular Dynamics, Inc.
• Ncardia
• LizarBio Therapeutics（Pluricell Biotech）
• Reprocell USA, Inc.
• Sumitomo Dainippon Pharma Co., Ltd.
• Takara Bio, Inc

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Induced pluripotent stem cells (iPSCs) market was valued at USD 1.45 billion in 2024 and is projected to exhibit strong growth throughout the forecast period, expanding at a compound annual growth rate (CAGR) of 9.60% through 2030.

The iPSCs market has emerged as a dynamic and high-potential segment within the broader regenerative medicine and cell therapy landscape. iPSCs are adult cells reprogrammed to a pluripotent state, enabling them to differentiate into virtually any cell type. This unique capability makes iPSCs a critical asset in both therapeutic development and biomedical research.

Key Market Drivers

Rising Incidence of Chronic Diseases

The global surge in chronic, non-communicable diseases-including cardiovascular diseases, diabetes, neurodegenerative disorders such as Alzheimer's and Parkinson's, and various cancers-is placing significant strain on healthcare systems. These conditions collectively account for approximately 75% of global mortality and represent substantial clinical and economic burdens across both developed and developing regions.

This trend is directly contributing to the accelerated adoption of iPSCs, which offer transformative potential in disease modeling, drug discovery, and regenerative treatment development. Chronic diseases are typically progressive and require long-term, often lifelong, management. Traditional therapies frequently fall short in addressing the root causes or providing curative solutions.

iPSCs, by contrast, enable the regeneration of damaged or diseased tissues using cells derived from the patient, offering a novel therapeutic pathway. Industry research indicates that a significant portion of biopharmaceutical and medtech executives are prioritizing disruptive innovations-such as cell and gene therapies, including CAR-T and CRISPR-over incremental improvements to existing drugs and devices. Notably, 32% of biopharma leaders are focusing on such innovations, while 30% of medtech stakeholders are shifting investment toward breakthrough platforms, with 24% favoring the development of high-risk, high-reward Class III medical devices.

This strategic redirection underlines the growing confidence in iPSC-based therapies as sustainable, personalized alternatives to conventional treatments.

Key Market Challenges

Safety and Efficacy Concerns

Despite the significant promise of iPSCs, safety and efficacy concerns represent major barriers to their widespread clinical adoption. One of the most critical safety risks involves tumorigenesis; iPSCs, when transplanted, have the potential to form teratomas-tumors comprising various cell types-posing serious safety implications for patients.

Additionally, although iPSCs are often derived from a patient's own cells, issues with immune compatibility can still arise. Particularly in allogeneic applications, where donor-derived iPSC therapies are used, the risk of immune rejection remains a concern and must be carefully managed.

Efficacy also presents a key challenge. Demonstrating consistent and meaningful therapeutic outcomes in both preclinical and clinical settings is essential to gain regulatory approval and clinical trust. Long-term efficacy data, especially for chronic and degenerative conditions, are still being established.

Furthermore, the lack of standardized protocols for iPSC generation, differentiation, and quality control contributes to variability in cell quality and function. This inconsistency can impede reproducibility, scalability, and broader commercialization efforts.

Key Market Trends

Growth of Personalized Medicine and Patient-Specific Therapies

The growing shift toward personalized medicine is among the most significant trends shaping the iPSCs market. The ability to develop therapies tailored to individual genetic and immunological profiles is revolutionizing treatment paradigms, especially for chronic and complex diseases.

iPSCs facilitate the creation of patient-specific therapies by reprogramming somatic cells into a pluripotent state. These cells can then be genetically corrected-if necessary-and differentiated into therapeutic cell types. This personalized approach significantly reduces the risk of immune rejection and enhances therapeutic efficacy, offering hope for conditions that were previously considered untreatable.

In addition, iPSCs are enabling the creation of highly accurate disease models that reflect the patient's unique pathology. These models are invaluable for studying disease mechanisms, evaluating drug responses, and designing customized treatment strategies.

By minimizing the likelihood of adverse reactions and improving clinical outcomes, patient-specific iPSC-based therapies are reshaping expectations in regenerative medicine and significantly advancing the frontier of precision healthcare.

Key Market Players

• Axol Bioscience Ltd.
• Cynata Therapeutics Limited
• Evotec SE
• Fate Therapeutics, Inc.
• FUJIFILM Cellular Dynamics, Inc.
• Ncardia
• LizarBio Therapeutics (Pluricell Biotech)
• Reprocell USA, Inc.
• Sumitomo Dainippon Pharma Co., Ltd.
• Takara Bio, Inc.

Report Scope:

In this report, the Global Induced Pluripotent Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Induced Pluripotent Stem Cells Market, By Derived Cell Type:

• Hepatocytes
• Fibroblasts
• Keratinocytes
• Neurons
• Others

Induced Pluripotent Stem Cells Market, By Application:

• Drug Development
• Regenerative Medicine
• Toxicity Testing
• Tissue Engineering
• Cell Therapy
• Disease Modeling

Induced Pluripotent Stem Cells Market, By End User:

• Research Institutions
• Other

Induced Pluripotent Stem Cells Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Market.

Available Customizations:

Global Induced Pluripotent Stem Cells market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Induced Pluripotent Stem Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, Others)
  • 5.2.2. By Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, Cell Therapy, Disease Modeling)
  • 5.2.3. By End user (Research Institutions, Other)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Induced Pluripotent Stem Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Derived Cell Type
  • 6.2.2. By Application
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Induced Pluripotent Stem Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Derived Cell Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End user
  • 6.3.2. Mexico Induced Pluripotent Stem Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Derived Cell Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End user
  • 6.3.3. Canada Induced Pluripotent Stem Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Derived Cell Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End user

7. Europe Induced Pluripotent Stem Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Derived Cell Type
  • 7.2.2. By Application
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Induced Pluripotent Stem Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Derived Cell Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End user
  • 7.3.2. Germany Induced Pluripotent Stem Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Derived Cell Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Induced Pluripotent Stem Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Derived Cell Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Induced Pluripotent Stem Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Derived Cell Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Induced Pluripotent Stem Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Derived Cell Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End user

8. Asia-Pacific Induced Pluripotent Stem Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Derived Cell Type
  • 8.2.2. By Application
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Induced Pluripotent Stem Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Derived Cell Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End user
  • 8.3.2. India Induced Pluripotent Stem Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Derived Cell Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End user
  • 8.3.3. South Korea Induced Pluripotent Stem Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Derived Cell Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End user
  • 8.3.4. Japan Induced Pluripotent Stem Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Derived Cell Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Induced Pluripotent Stem Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Derived Cell Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End user

9. South America Induced Pluripotent Stem Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Derived Cell Type
  • 9.2.2. By Application
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Induced Pluripotent Stem Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Derived Cell Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End user
  • 9.3.2. Argentina Induced Pluripotent Stem Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Derived Cell Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End user
  • 9.3.3. Colombia Induced Pluripotent Stem Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Derived Cell Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End user

10. Middle East and Africa Induced Pluripotent Stem Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Derived Cell Type
  • 10.2.2. By Application
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Induced Pluripotent Stem Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Derived Cell Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End user
  • 10.3.2. Saudi Arabia Induced Pluripotent Stem Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Derived Cell Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End user
  • 10.3.3. UAE Induced Pluripotent Stem Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Derived Cell Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Axol Bioscience Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Cynata Therapeutics Limited
• 15.3. Evotec SE
• 15.4. Fate Therapeutics, Inc.
• 15.5. FUJIFILM Cellular Dynamics, Inc.
• 15.6. Ncardia
• 15.7. LizarBio Therapeutics (Pluricell Biotech)
• 15.8. Reprocell USA, Inc.
• 15.9. Sumitomo Dainippon Pharma Co., Ltd.
• 15.10. Takara Bio, Inc

16. Strategic Recommendations

17. About Us & Disclaimer